Disease‐specific measure of quality of life for myasthenia gravis
- 11 August 2008
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 38 (2), 947-956
- https://doi.org/10.1002/mus.21016
Abstract
In 2000 a Task Force of the Myasthenia Gravis Foundation of America recommended development of a quality of life (QOL) measure specific for myasthenia gravis (MG). Extant investigations have relied solely on assessment of physical aspects of daily living in conceptualizing QOL, despite research that emphasizes the importance of including psychological factors. In the present study we developed a QOL questionnaire specific to MG (MG-QOL) that assesses both physical and psychological aspects of function. The MG-QOL questionnaire was administered as a secondary measure of efficacy in a recently completed prospective trial of mycophenolate mofetil involving 80 MG patients. Comparisons indicated that the MG-QOL performed better than a nondisease-specific measure of QOL, the SF-36, in demonstrating disease change as assessed by the primary measure, the Quantitative MG score (QMG). The MG-QOL correlated highly with the SF-36, and demonstrated stronger associations with independent physical ability ratings. Results from this study support the use of this new measure of QOL, both clinically and in treatment trials of MG. Muscle Nerve 38: 947–956, 2008Keywords
This publication has 20 references indexed in Scilit:
- Disease‐specific measure of quality of life for myasthenia gravisMuscle & Nerve, 2008
- A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravisNeurology, 2008
- Less is more, or almost as much: A 15‐item quality‐of‐life instrument for myasthenia gravisMuscle & Nerve, 2008
- Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL)Neurology, 2007
- Myasthenia Gravis and Lambert‐Eaton SyndromeTherapeutic Apheresis, 2002
- Reliability Testing of the Quantitative Myasthenia Gravis ScoreaAnnals of the New York Academy of Sciences, 1998
- Validation of the Functional Assessment of Multiple Sclerosis quality of life instrumentNeurology, 1996
- A Clinical Therapeutic Trial of Cyclosporine in Myasthenia GravisaAnnals of the New York Academy of Sciences, 1993
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Immunointervention with cyclosporin A in autoimmune neurological disordersJournal of Autoimmunity, 1992